BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Azacitidine (Onureg) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Azacitidine (Onureg)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04799275-11033@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Azacitidine (Onureg): Phase 2/3 readout est. (NCT04799275)
DESCRIPTION:Azacitidine (Onureg)\, phase 2/3.\nStudy: Testing CC-486 (Oral 
 Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older 
 With Newly Diagnosed Diffuse Large B Cell Lymphoma\nEstimated primary comp
 letion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /azacitidine-onureg#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04799275
URL:https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05287568-11033@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:Azacitidine (Onureg): Phase 1 readout est. (NCT05287568)
DESCRIPTION:Azacitidine (Onureg)\, phase 1\, Acute Myeloid Leukemia.\nStudy
 : CC-486 and Venetoclax for Acute Myeloid Leukemia\nEstimated primary comp
 letion: 23 March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/azacitidine-onureg#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05287568
URL:https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05162976-11033@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Azacitidine (Onureg): Phase 1 readout est. (NCT05162976)
DESCRIPTION:Azacitidine (Onureg)\, phase 1.\nStudy: CC-486 and Nivolumab fo
 r the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
 \nEstimated primary completion: 27 April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/azacitidine-onureg#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05162976
URL:https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04803201-11033@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270519
DTEND;VALUE=DATE:20270520
SUMMARY:Azacitidine (Onureg): Phase 2 readout est. (NCT04803201)
DESCRIPTION:Azacitidine (Onureg)\, phase 2.\nStudy: Testing the Addition of
  Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
 \nEstimated primary completion: 19 May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/azacitidine-onureg#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04803201
URL:https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06370000-11033@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Azacitidine (Onureg): Phase 4 readout est. (NCT06370000)
DESCRIPTION:Azacitidine (Onureg)\, phase 4\, Acute Myeloid Leukemia.\nStudy
 : Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leuk
 emia (AML) Suffering From Health-Inequality\nEstimated primary completion:
  31 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aza
 citidine-onureg#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06370000
URL:https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05469737-11033@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Azacitidine (Onureg): Phase 2/3 readout est. (NCT05469737)
DESCRIPTION:Azacitidine (Onureg)\, phase 2/3.\nStudy: A Study to Compare th
 e Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) 
 Versus Placebo Plus BSC in Participants With International Prognostic Scor
 ing System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Synd
 rome (MDS)\nEstimated primary completion: 31 July 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05469737
URL:https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463768-11033@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Azacitidine (Onureg): Phase 2 readout est. (NCT07463768)
DESCRIPTION:Azacitidine (Onureg)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib t
 o Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leuke
 mia (AML) and IDH1 Mutation\, in Complete Remission After Intensive Chemot
 herapy.\nEstimated primary completion: September 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07463768
URL:https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
